Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE

This study is a randomized, double-blind, placebo controlled trial to evaluate the safety and efficacy of Inhaled Treprostinil administered through 20 weeks to subjects with pulmonary hypertension due to parenchymal lung disease.

Treprostinil is a chemically stable tricyclic analogue of prostacyclin that is well-characterized and approved for the treatment of PAH. Prostacyclins act as vasodilators and inhibitors of platelet aggregation. This allows for substantial decreases in pulmonary arterial pressures and resistance.

Patients will have 6-8 visits over the course of 16-20 weeks. The primary endpoint for this study is the 6-minute walk distance.

  • Study Sponsor: United Therapeutics

  • Start Date: July 2017

  • Estimated Primary Completion Date: July 2018

Participating Clinics at Member ILD Centers